Ticker,Title,Post_Date,Upvotes,Num_Comments
PFE,Pfizer (PFE) Is Materially Undervalued; Pipeline Underestimated by a Wide Margin - Drugs in Phase III trials suggest $2.7 - $5 Billion in additional annual revenue,2025-05-20,79,32
